2014
DOI: 10.1186/preaccept-1169847631131229
|View full text |Cite|
|
Sign up to set email alerts
|

The effects of dexamethasone on the proliferation and apoptosis of human ovarian cancer cells induced by paclitaxel

Abstract: Background: Dexamethasone (DEX) has been routinely used as a pre-treatment in the clinical application of paclitaxel (PTX) to treat ovarian cancer. However, PTX-induced apoptosis might be inhibited by DEX. This study was undertaken to investigate the effects of DEX on the apoptosis induced by PTX. Methods: Both of SKOV-3 and HO-8910 human ovarian cancer cells were divided into four groups: (1) untreated (Con); (2) treated with DEX (0.1 μM) alone; (3) treated with PTX (50 nM); and (4) pre-treated with DEX (0.1 … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 25 publications
0
1
0
Order By: Relevance
“…The exact mechanism of such DDI is unknown, as albendazole pharmacokinetics parameters are increased in the presence of concomitant dexamethasone treatment [90]. In an in vivo model of human ovarian carcinoma xenocraft on nude mice, a premedication with dexamethasone reduced the inhibitory effect of paclitaxel, another taxane family antitumor agent, on tumor growth by approximately 20% [91]. In a model of rheumatoid arthritis, a synergistic effect was observed between tofacitinib and dexamethasone, on paw growth with a 0.76 interaction factor [92].…”
Section: (C) Interaction By Unknown or Unspecified Mechanismsmentioning
confidence: 99%
“…The exact mechanism of such DDI is unknown, as albendazole pharmacokinetics parameters are increased in the presence of concomitant dexamethasone treatment [90]. In an in vivo model of human ovarian carcinoma xenocraft on nude mice, a premedication with dexamethasone reduced the inhibitory effect of paclitaxel, another taxane family antitumor agent, on tumor growth by approximately 20% [91]. In a model of rheumatoid arthritis, a synergistic effect was observed between tofacitinib and dexamethasone, on paw growth with a 0.76 interaction factor [92].…”
Section: (C) Interaction By Unknown or Unspecified Mechanismsmentioning
confidence: 99%
“…The Publisher and Editor regretfully retract this article [ 1 ] because the peer-review process was inappropriately influenced and compromised. As a result, the scientific integrity of the article cannot be guaranteed.…”
Section: Retractionmentioning
confidence: 99%